A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.
Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.
Researchers showed that the company's chips can be used to rapidly isolate exosomes from plasma or whole blood samples, allowing testing of cancer diagnostic markers.
CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
Jean-Laurent Casanova aims to identify single-gene mutations that compromise the immunity of normally healthy individuals and lead to severe infectious disease.
Owlstone will give AstraZeneca access to its Breath Biopsy Services to identify breath-based biomarkers for stratifying and treating asthma and COPD patients.
CU Denver and UC San Francisco teams are independently performing whole-genome sequencing to find genes involved in reduced efficacy of a common bronchodilator drug.
The researchers found that the expression of certain genes was better at helping them predict when Ebola would develop than indications of infection like fever.
